Daiichi Sankyo Europe GmbH

Featured Stories

For the last ten years we as Daiichi Sankyo Europe have supported young graduates from the Ludwig-Maximilians-University in Munich (LMU). read more...

The new Daiichi Sankyo Group’s Value Report is now available! The report includes business facts & figures, information about Daiichi Sankyo’s growth potential, CSR activities and much more. read more...

Featured News

Date	Description
10/18/2019 Products	Daiichi Sankyo Receives Negative CHMP Opinion for FLT3 Inhibitor Quizartinib for Treatment of Patients with Relapsed/Refractory FLT3-ITD AML	PDF
10/17/2019 Products	[Fam-] Trastuzumab Deruxtecan (DS-8201) Granted FDA Priority Review for Treatment of Patients with HER2 Positive Metastatic Breast Cancer	PDF
10/17/2019 Products	European results from Global ETNA-AF registry show low bleeding and low cardiovascular event rates in elderly NVAF patients on LIXIANA®▼ (edoxaban)	PDF
09/11/2019 Research	The Global CLEAR Cardiovascular Outcomes Trial for Bempedoic Acid Completes Patient Enrolment	PDF
09/10/2019 Research	Updated Clinical Results and New Biomarker Analyses Presented for Daiichi Sankyo’s DS-1062 in Patients with Advanced NSCLC at 2019 World Conference on Lung Cancer	PDF
show all

Dear User, This website provides you with information only for healthcare professionals. According to the drug promotion code, we are only able to allow healthcare professionals like physicians and pharmacists to have full access to our website. To visit our page please login.

Daiichi Sankyo
Doc Check

Support For Young Talents

Value Report 2019